Education
About Us
Working with TipRanks
Follow Us
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
CTXR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $15.27
Previous CloseN/A
Volume111.57K
Average Volume (3M)421.93K
Market Cap
$22.46M
Enterprise Value$15.80M
Total Cash (Recent Filing)$26.41K
Total Debt (Recent Filing)$931.79K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Feb 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding17,012,192
10 Day Avg. Volume468,091
30 Day Avg. Volume421,930
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue101.30
Enterprise Value/Gross Profit-96.50
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$6.00Price Target Upside337.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMino-Lok has the potential to salvage the catheter with a 100% salvage rate in Phase 2b.
CommercializationCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.
Regulatory ApprovalThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.
Bears Say
Capital RequirementsCitius Pharma reported a net loss with very limited cash, indicating the need to raise capital soon.
Financial ConstraintsFinancial constraints are elevating risks to bring Lymphir to market and to advance Mino-Lok.
Regulatory TimelineCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.
Citius Pharmaceuticals News
CTXR FAQ
What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.65 and its highest was $15.27 in the past 12 months.
What is Citius Pharmaceuticals’s market cap?
Citius Pharmaceuticals’s market cap is $22.46M.
When is Citius Pharmaceuticals’s upcoming earnings report date?
Citius Pharmaceuticals’s upcoming earnings report date is Feb 06, 2026 which is in 161 days.
How were Citius Pharmaceuticals’s earnings last quarter?
Citius Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.505 by -$0.295.
Is Citius Pharmaceuticals overvalued?
According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued.
Does Citius Pharmaceuticals pay dividends?
Citius Pharmaceuticals does not currently pay dividends.
What is Citius Pharmaceuticals’s EPS estimate?
Citius Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Citius Pharmaceuticals have?
Citius Pharmaceuticals has 17,012,192 shares outstanding.
What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
Citius Pharmaceuticals reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.505. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Citius Pharmaceuticals?
Currently, no hedge funds are holding shares in CTXR
Citius Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (337.96% Upside)
$6.00 (337.96% Upside)
Blogger Sentiment
Bullish
CTXR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 3.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.74%
12-Months-Change
Fundamentals
Return on Equity
-53.42%
Trailing 12-Months
Asset Growth
31.50%
Trailing 12-Months
Company Description
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Stock 12 Month Forecast
Average Price Target
$6.00
▲(337.96% Upside)
Technical Analysis
Ownership Overview
61.19% Insiders
5.28% Mutual Funds
1.07% Other Institutional Investors
32.00% Public Companies and
Individual Investors